Human Factor-related Apoptosis ligand,FASL ELISA Kit

Code CSB-E04544h
Size 96T,5×96T,10×96T
Price Request a Quote or Start an on-line Chat
Trial Size 24T ELISA Kit Trial Size (Only USD$150/ kit)
* Sample kit cost can be deducted as a $30 credit for each 96-assay kit of the same analyte and brand you subsequently purchase in six months till depleted. Apply now

Product Details

Target Name
Fas ligand (TNF superfamily, member 6)
Alternative Names
ALPS1B ELISA Kit; Apoptosis (APO 1) antigen ligand 1 ELISA Kit; Apoptosis antigen ligand 1 ELISA Kit; Apoptosis antigen ligand ELISA Kit; APT1LG1 ELISA Kit; APTL ELISA Kit; CD178 ELISA Kit; CD178 antigen ELISA Kit; CD95 ligand ELISA Kit; CD95-L ELISA Kit; CD95L ELISA Kit; CD95L protein ELISA Kit; Fas antigen ligand ELISA Kit; Fas L ELISA Kit; Fas ligand (TNF superfamily member 6) ELISA Kit; Fas ligand ELISA Kit; FASL ELISA Kit; Fasl Fas ligand (TNF superfamily member 6) ELISA Kit; FASLG ELISA Kit; Generalized lymphoproliferative disease ELISA Kit; Gld ELISA Kit; soluble form ELISA Kit; TNFL6_HUMAN ELISA Kit; TNFSF6 ELISA Kit; Tumor necrosis factor (ligand) superfamily member 6 ELISA Kit; Tumor necrosis factor ligand superfamily member 6 ELISA Kit
Uniprot No.
Homo sapiens (Human)
Sample Types
serum, plasma, cell culture supernates
Detection Range
31.25 pg/mL-2000 pg/mL
7.81 pg/mL
Assay Time
Sample Volume
Detection Wavelength
450 nm
Research Area
Cell Biology
Assay Principle
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
To assess the linearity of the assay, samples were spiked with high concentrations of human FASL in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
1:1Average %95
Range %89-98
1:2Average %98
Range %93-102
1:4Average %94
Range %89-97
1:8Average %92
Range %87-94
The recovery of human FASL spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample TypeAverage % RecoveryRange
Serum (n=5) 9389-97
EDTA plasma (n=4)8882-94
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
20002.472 2.624 2.548 2.423
10001.568 1.467 1.518 1.393
5000.846 0.866 0.856 0.731
2500.488 0.474 0.481 0.356
1250.321 0.332 0.327 0.202
62.50.255 0.267 0.261 0.136
31.250.192 0.198 0.195 0.070
00.124 0.126 0.125
and FAQs
Store at 2-8°C. Please refer to protocol.
Lead Time
3-5 working days after you place the order, and it takes another 3-5 days for delivery via DHL or FedEx

This Human FASLG ELISA Kit was designed for the quantitative measurement of Human FASLG protein in serum, plasma, cell culture supernates. It is a Sandwich ELISA kit, its detection range is 31.25 pg/mL-2000 pg/mL and the sensitivity is 7.81 pg/mL.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

(From Uniprot)
Cytokine that binds to TNFRSF6/FAS, a receptor that transduces the apoptotic signal into cells. Involved in cytotoxic T-cell-mediated apoptosis, natural killer cell-mediated apoptosis and in T-cell development. Initiates fratricidal/suicidal activation-induced cell death (AICD) in antigen-activated T-cells contributing to the termination of immune responses. TNFRSF6/FAS-mediated apoptosis has also a role in the induction of peripheral tolerance. Binds to TNFRSF6B/DcR3, a decoy receptor that blocks apoptosis.; Induces FAS-mediated activation of NF-kappa-B, initiating non-apoptotic signaling pathways. Can induce apoptosis but does not appear to be essential for this process.; Cytoplasmic form induces gene transcription inhibition.
Gene References into Functions
  1. FASLG single-nucleotide polymorphisms rs763110 and rs5030772 are involved in the pathogenesis of Idiopathic Aplastic Anemia PMID: 29611722
  2. Evaluation of FAS/FASL polymorphisms can predict lack of response to BCG immunotherapy and prevent the loss of valuable time before such alternative treatments as early cystectomy are initiated. PMID: 29453645
  3. results suggest that miR-21 regulates the apoptosis of keloid fibroblasts via targeting FasL, and caspase-8 and the mitochondria-mediated apoptotic signaling pathway is involved in this process. PMID: 29527928
  4. the detailed mechanisms of FasL-Fas necroptosis can help in understanding the processes of elimination of tumor cells that have blocked apoptosis signal transduction PMID: 30103900
  5. Increased FASL expression is associated with dermatofibrosarcoma protuberans. PMID: 29509956
  6. data demonstrated that FASL-844C/T SNP was substantially associated with idiopathic azoospermia, indicating that it might be a genetic predisposing factor of idiopathic azoospermia in the Western of Iran. PMID: 28942044
  7. platelet-derived FasL has a role in apoptosis in stroke PMID: 27608763
  8. The Fas-ligand SNP and TNF gene -308 SNP are associated with anti-TNF treatment response in Crohn's disease and may help select patients likely to benefit from therapy. PMID: 28785150
  9. serum levels of soluble FAS ligand (sFASL) and interferon gamma (IFN-gamma) were analyzed and correlated with sFGL2 levels in Hepatitis C Virus-Infected Patients and Hepatocellular Carcinoma Patients. PMID: 28609212
  10. Study shows for the first time that CD95L activates NHE1, which thereby enhances cell migration. Using a combination of inhibitors and site-directed mutagenesis, results subsequently demonstrate that this mechanism occurs through a modification of NHE1 cooperative response to intracellular protons and that it involves both the Akt and RhoA-dependent pathways. PMID: 27302366
  11. These results suggest that the FasL -844T>C single nucleotide polymorphism is implicated in the susceptibility to hepatitis C virus in Egyptian patients and firstly report the involvement of TRAIL gene polymorphism in the risk of the disease. PMID: 28587866
  12. Increased activation of B-cells is present following successful Tuberculosis treatment, and the expression of FASLG and IL5RA could potentially be utilized as a signature to monitor treatment response. PMID: 27682872
  13. This study highlights a coordinated neurovascular development instructed by CNS macrophage-derived CD95L. PMID: 28514658
  14. FasL -844C>T polymorphism plays a protective role against Head and Neck Cancer development in Asian population. PMID: 29419701
  15. The Fas mRNA expression ratio was unchanged upon MTX treatment, but the FasL mRNA expression ratio was significantly higher in MTX-treated than nontreated polyps. In addition, the expression levels of the Fas and FasL proteins were significantly higher in polyps treated with both 10 and 100 muM MTX compared with nontreated polyps. PMID: 28468172
  16. Results show that the FasL:Fas complex shares structural features with the FasL:DcR3 assembly and the glycosylation contributes to the activity of soluble FasL PMID: 27806260
  17. FASLG c.-844TC genotype may be protective against familial mediterranean fever in the Turkish population. PMID: 28442396
  18. The rs763110 TT genotype significantly increased the risk of cervical cancer compared with the CC/CT genotype. Patients carrying this genotype presented a lower cancerous FASL expression than that of the CC/CT genotypes. OCT1 was recruited to the FASL promoter region and regulated the FASL gene transcription by interacting with C/EBPbeta. PMID: 27790710
  19. Inhibition of miR-149-5p can induce apoptosis in THP-1 cells. These inductive effects might be via targeting FASLG and activating FADD and caspases. PMID: 28013316
  20. FasL gene polymorphism is associated with Hashimoto's thyroiditis. PMID: 27572459
  21. There is a positive correlation of the serum level of sFasL ( Fas/FasL axis )with uptake index of parotid gland in our expectation. In addition, liver injury involvement in SS patients showed decreased level of sFasL. Furthermore, we here also observed that the protective cytokine IL-10 expression was positively correlated with sFasL expression PMID: 28326325
  22. The results of this study did show an initial decrease in sCD95L, but this was followed by a steady increase above initially measured concentrations. Furthermore, we found that patients with clinically documented neurological remission showed higher sCD95L serum concentrations than patients without remission. PMID: 27089864
  23. suppression of EP1 prevented RAMA-induced FasL suppression in CLT85 cells at both the mRNA and protein levels PMID: 26211005
  24. In sprint-trained male athletes, FasL, miR-21, and miR-146a were measured cross-sectionally (n = 67, 18-90 yrs) and serum FasL, miR-21, and miR-146a and their aging-related associations with physical performance were assessed over a 10-year follow-up (n = 49, 50-90 yrs). PMID: 28127562
  25. In women with endometriosis, immunostaining for Fas-Ligand in the eutopic endometrium was stronger in the epithelial cells of secretory phase, while the epithelial cells of endometriotic lesions showed a significantly stronger staining for Fas-Ligand independently from the menstrual phase PMID: 26156853
  26. The study identified Fas ligand (FASLG) as the target of let-7e-5p, and FASLG knockdown increased the migration and tube formation of endothelial progenitor cell. PMID: 26826505
  27. Case Reports: patients with autosomal recessive inheritance of ALPS-FASLG have a severe phenotype and a partial defect in activation-induced cell death in T- and B-cell lines. PMID: 26334989
  28. No mutation or variation could be found in FASL in patients or controls. PMID: 26690594
  29. FASL, granzyme B, and cytochrome c blood expression reflects breast cancer progression and response to therapy. (Review) PMID: 27117663
  30. No association has been found between FASL promoter polymorphisms and predisposition to HIV infection. PMID: 26429326
  31. FASL expression is an independent marker for earlier disease relapse and disease-specific death in oral squamous cell carcinoma. PMID: 26400345
  32. These data indicate that Epstein-Barr virus exosomes derived from EBV-infected cells are taken up by non-infected cells and induce apoptosis via the extrinsic pathway, and that exosomes trigger apoptosis through the FasL pathway. PMID: 26467838
  33. The expression of Ki67 and FasL is closely related to the occurrence and development of cervical carcinoma. PMID: 26345794
  34. Data suggest Faim2/LFG (lifeguard protein) protects against FasL-/Fas ligand-induced apoptosis by down-regulating calcium release from endoplasmic reticulum in cortical neurons. PMID: 26582200
  35. In patients with either Crohn's disease or ulcerative colitis, the extent of endothelial FasL expression was elevated in the submucosa and associated with an elevated number of lymphoid follicles. PMID: 26374830
  36. Th1 cells express high level of FAS-ligand (FASL), which interacts with FAS and leads to caspases' cleavage and ultimately to cell death. PMID: 25950471
  37. Fas Ligand Deficiency Impairs Tumor Immunity by Promoting an Accumulation of Monocytic Myeloid-Derived Suppressor Cells PMID: 26359460
  38. FASL -844 T > C promoter single nucleotide polymorphism is associated with oral cancers. PMID: 25944167
  39. Death induced by CD95R/L elimination (DICE) and CD95-mediated apoptosis have opposing roles in eliminating cancer stem cells (CSCs)and non-CSCs. PMID: 25366259
  40. Membrane-bound FasL mediates platelets-induced apoptosis, whereas Bax/Bak signaling is not required but reinforces platelets-induced apoptosis. PMID: 26232171
  41. DcR3 enhances ERK1/2 phosphorylation and opposes FasL signaling in pancreatic cancer cells PMID: 26102031
  42. MiR-21 up-regulation mediates glioblastoma cancer stem cells apoptosis and proliferation by targeting FASLG. PMID: 25394756
  43. FasL -844 CC combined with the Fas -1377 G allele is a protective factor against ESCC. PMID: 24473454
  44. High Fas expression promotes chemoresistance in gastrointestinal cancer by up-regulating P-glycoprotein. PMID: 25333257
  45. There was no correlation between TGF-beta1 levels and HBV load, but there is a positive correlation between sFas levels and HBV load. PMID: 25990938
  46. data strongly indicate that the inhibition of ceramide conversion to complex sphingolipids by D609 is accompanied by an enhancement of FasL-induced caspase-dependent and -independent cell death in T lymphocytes. PMID: 22942738
  47. during spontaneous miscarriages, the increased FasL-expressing population could be a part of an M1 phenotype participating in Fas/FasL-related apoptosis. PMID: 22942752
  48. these findings provide novel experimental evidences supporting that VC or/and VE could reduce p,p'-DDT-induced cytotoxicity of HL-7702 cells via the ROS-mediated mitochondrial pathway and NF-kappaB/FasL pathway. PMID: 25464339
  49. Fas ligand correlates with the documented degree of atrial apoptosis and atrial fibrosis in right atrial appendage tissue after cardiac surgery. PMID: 23790081
  50. The T/T genotype and the T allele of the c.-844T>C polymorphism were associated with increased occurrence of keratoconus, while the C allele was associated with decreased keratoconus occurrence. PMID: 25169582

Show More

Hide All

Involvement in disease
Autoimmune lymphoproliferative syndrome 1B (ALPS1B)
Subcellular Location
Cell membrane; Single-pass type II membrane protein. Cytoplasmic vesicle lumen. Lysosome lumen.; [Tumor necrosis factor ligand superfamily member 6, soluble form]: Secreted.; [FasL intracellular domain]: Nucleus.
Protein Families
Tumor necrosis factor family
Database Links

HGNC: 11936

OMIM: 134638

KEGG: hsa:356

STRING: 9606.ENSP00000356694

UniGene: Hs.2007

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1